Canagliflozin Export Market Intelligence: India's 40 Suppliers Shipping to 23 Countries — TransData Nexus 2026

Q: Who are the top canagliflozin exporters from India?

The top canagliflozin exporters from India are: 1. LOTUS INTERNATIONAL — $192.4K (21.8% market share); 2. SHREE SSD PHARMA PRIVATE LIMITED — $190.0K (21.5% market share); 3. GANPATI EXIM INC — $143.9K (16.3% market share); 4. LAWRENCE WALTER — $141.0K (16.0% market share); 5. PLEASANT EXPORTS — $56.0K (6.3% market share). Together they account for 81.9% of India's total canagliflozin export value.

Q: What is the total export value of canagliflozin from India?

The total export value of canagliflozin from India is $883.4K USD, recorded across 873 shipment transactions from 40 active exporters to 23 destination countries. The average shipment value is $1.0K.

Q: Which countries import canagliflozin from India?

India exports canagliflozin to 23 countries worldwide. The top importing countries are: SINGAPORE (60.0% share, $529.8K), MAURITIUS (15.6% share, $137.8K), BELGIUM (9.7% share, $85.4K), SWITZERLAND (6.9% share, $60.6K), TAIWAN (4.1% share, $35.9K). These five markets account for 96.2% of total export value.

Q: What is the average price of canagliflozin exports from India?

The average unit price for canagliflozin exports from India is $26.62 USD per unit, with prices ranging from $0.08 to $3723.03 depending on formulation, packaging, and order volume. The total market is valued at $883.4K across 873 shipments.

Q: Which ports handle canagliflozin exports from India?

The primary ports for canagliflozin exports from India are DELHI AIR CARGO ACC (INDEL4) (34.8% of shipments), DELHI AIR (21.2% of shipments), SAHAR AIR (19.7% of shipments), SAHAR AIR CARGO ACC (INBOM4) (6.9% of shipments), Delhi Air (6.6% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of canagliflozin?

India is one of the world's leading exporters of canagliflozin due to its large base of 40 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports canagliflozin to 23 countries, demonstrating 12% global market coverage.

Q: What certifications do Indian canagliflozin exporters need?

Indian canagliflozin exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import canagliflozin from India?

There are 66 registered buyers importing canagliflozin from India, spread across 23 countries. The repeat buyer rate is 59.1%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top canagliflozin supplier from India?

LOTUS INTERNATIONAL is the leading canagliflozin exporter from India with a market share of 21.8% and total export value of $192.4K across 16 shipments. The top 5 suppliers together control 81.9% of total export value.

Suresh Sormare

Canagliflozin

India Pharmaceutical Trade Intelligence

$883.4K40 Suppliers23 CountriesHS 30049099

ExportsIndia → SINGAPORE60.0%India → MAURITIUS15.6%

ImportsITALY → India$1.5B SWITZERLAND → India$661.5K

#1 Supplier: LOTUS INTERNATIONAL

Canagliflozin Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Canagliflozin to the World

Between 2022 and 2026, India exported $883.4K worth of canagliflozin across 873 verified shipments to 23 countries — covering 12% of world markets in the Advanced Diabetes Medications segment. The largest destination is SINGAPORE (60.0%). LOTUS INTERNATIONAL leads with a 21.8% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Canagliflozin export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Canagliflozin export data snapshot — $883.4K · 40 exporters · 23 countriesTransData Nexus · Indian Customs Data

Top Canagliflozin Exporters from India

40 active exporters · Ranked by export value

View all 40 →

Top Canagliflozin Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	LOTUS INTERNATIONAL	$192.4K	16	2	21.8%
2	SHREE SSD PHARMA PRIVATE LIMITED

Top Countries Importing Canagliflozin from India

23 destination markets · Ranked by import value

All 23 countries →

Top Countries Importing Canagliflozin from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	SINGAPORE	$529.8K	60.0%
2	MAURITIUS	$137.8K	15.6%
3	BELGIUM	$85.4K	9.7%
4	SWITZERLAND	$60.6K	6.9%
5	TAIWAN	$35.9K	4.1%
6	MYANMAR	$20.9K	2.4%
7	UNITED STATES	$1.7K	0.2%
8	HONG KONG	$1.6K	0.2%
9	KENYA	$1.4K	0.2%
10	DOMINICAN REPUBLIC	$1.4K	0.2%

SINGAPORE is India's largest canagliflozin export destination, absorbing 60.0% of total exports worth $529.8K. The top 5 importing countries — SINGAPORE, MAURITIUS, BELGIUM, SWITZERLAND, TAIWAN — together account for 96.2% of India's total canagliflozin export value. The remaining 18 destination countries collectively receive the other 3.8%, indicating a focused distribution strategy targeting key markets.

Who Supplies Canagliflozin to India?

10 origin countries · Total import value: $1.5B

India imports canagliflozin from 10 countries with a combined import value of $1.5B. The largest supplier is ITALY ($1.5B, 70 shipments), followed by SWITZERLAND and UNITED STATES. All values are from Indian Customs (DGFT) import records.

Countries Supplying Canagliflozin to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	ITALY	$1.5B	70	99.9%
2	SWITZERLAND	$661.5K	1	0.0%
3	UNITED STATES	$49.2K	6	0.0%
4	BELGIUM	$49.2K	5	0.0%
5	CANADA	$16.6K	18	0.0%
6	UNITED KINGDOM	$1.9K	3	0.0%
7	IRELAND	$1.8K	4	0.0%
8	GERMANY	$809	2	0.0%
9	PORTUGAL	$737	2	0.0%
10	PHILIPPINES	$10	1	0.0%

ITALY is the largest supplier of canagliflozin to India, accounting for 99.9% of total import value. The top 5 origin countries — ITALY, SWITZERLAND, UNITED STATES, BELGIUM, CANADA — together supply 100.0% of India's canagliflozin imports. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Canagliflozin

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, the FDA approved canagliflozin (Invokana) in March 2013 for the treatment of type 2 diabetes. Subsequently, in August 2014, the FDA approved Invokamet, a combination of canagliflozin and metformin hydrochloride, expanding treatment options for patients.

As of March 2026, the FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for generic versions of canagliflozin, indicating a competitive market landscape. The presence of 40 active Indian exporters supplying canagliflozin underscores India's significant role in the global supply chain.

Regarding safety communications, in May 2016, the FDA issued a Drug Safety Communication highlighting an increased risk of leg and foot amputations associated with canagliflozin use. Healthcare professionals were advised to monitor patients for signs of complications and consider discontinuing the drug if necessary.

2EU & UK Regulatory Framework

The European Medicines Agency (EMA) granted marketing authorization for Invokana in November 2013, approving it for adults with type 2 diabetes to improve glycemic control. (ema.europa.eu) In July 2025, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended extending the indication to include children aged 10 years and older, reflecting an expansion in the drug's approved use. (ema.europa.eu)

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) issued safety communications in June 2016 and March 2017 regarding an increased risk of lower limb amputations, primarily affecting the toes, in patients treated with canagliflozin. Healthcare professionals were advised to monitor patients closely and consider discontinuing the drug if complications arose. (gov.uk)

Compliance with EU Good Manufacturing Practice (GMP) requirements is mandatory for manufacturers supplying canagliflozin to the European market, ensuring product quality and patient safety.

3WHO Essential Medicines & Global Standards

As of March 2026, canagliflozin is not listed on the World Health Organization's Model List of Essential Medicines. However, it is included in various pharmacopoeias, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), establishing standardized quality benchmarks for the drug.

4India Regulatory Classification

In India, canagliflozin is classified under Schedule H of the Drugs and Cosmetics Rules, 1945, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for canagliflozin as of March 2026, allowing market-driven pricing. For export purposes, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with regulatory requirements.

5Patent & Exclusivity Status

The primary patent for canagliflozin expired in March 2024, opening the market to generic competition. This has led to increased participation from Indian exporters, with 40 active suppliers and a total export value of $0.9 million USD from 2022 to 2026.

6Recent Industry Developments

In July 2025, the EMA's CHMP recommended extending the indication for Invokana to include pediatric patients aged 10 years and older, broadening the therapeutic scope of canagliflozin. (ema.europa.eu)

In March 2025, the NPPA conducted a review of anti-diabetic medications, including canagliflozin, to assess pricing and accessibility, though no immediate price controls were implemented.

In January 2025, the FDA approved a new generic version of canagliflozin, enhancing market competition and potentially reducing costs for patients.

In December 2024, the WHO updated its guidelines on the management of type 2 diabetes, acknowledging the role of SGLT2 inhibitors like canagliflozin in reducing cardiovascular risk.

In November 2024, the Indian Ministry of Health and Family Welfare issued a directive to monitor the safety profile of SGLT2 inhibitors, including canagliflozin, in response to global safety concerns.

These developments reflect the dynamic regulatory and market environment surrounding canagliflozin, emphasizing the importance of ongoing vigilance and compliance for stakeholders involved in its production and distribution.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Canagliflozin

Retail & reference prices across 9 markets vs. India FOB export price of $26.62/unit

Global Price Benchmark for Canagliflozin across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$12.00	USD	According to the FDA's Orange Book, Canagliflozin is approved for use in the United States.
United Kingdom	$11.05	GBP	As per the NHS Drug Tariff, Canagliflozin is listed for use within the National Health Service.
Germany	$11.20	EUR	The European Medicines Agency (EMA) has authorized the use of Canagliflozin in Germany.
Australia	$10.50	AUD

Supply Chain Risk Assessment — Canagliflozin

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

Canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor used in the treatment of type 2 diabetes, is primarily manufactured in India. The production of its Active Pharmaceutical Ingredient (API) relies on Key Starting Materials (KSMs) and intermediates, a significant portion of which are sourced from China. According to the U.S. Pharmacopeia, 41% of KSMs used in U.S.-approved APIs are solely sourced from China, highlighting a substantial dependency on Chinese suppliers.

This reliance poses a risk to the supply chain, as any disruptions in China's production or export activities can directly impact the availability of Canagliflozin APIs. For instance, geopolitical tensions or regulatory changes in China could lead to supply shortages, affecting global pharmaceutical manufacturing.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data indicates that the top five Indian exporters of Canagliflozin account for 81.9% of the total export value, with LOTUS INTERNATIONAL leading at a 21.8% share. This high supplier concentration increases the risk of supply disruptions, as issues affecting these key exporters—such as operational challenges or regulatory non-compliance—could significantly impact global supply.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic API production and reduce dependency on imports. However, the effectiveness of this initiative in diversifying the supplier base for Canagliflozin remains to be fully realized.

Access Complete Canagliflozin Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 873 transactions across 23 markets.

Request Demo View Pricing

Frequently Asked Questions — Canagliflozin Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top canagliflozin exporters from India?

The leading canagliflozin exporters from India are LOTUS INTERNATIONAL, SHREE SSD PHARMA PRIVATE LIMITED, GANPATI EXIM INC, and 11 others. LOTUS INTERNATIONAL leads with 21.8% market share ($192.4K). The top 5 suppliers together control 81.9% of total export value.

What is the total export value of canagliflozin from India?

The total export value of canagliflozin from India is $883.4K, recorded across 873 shipments from 40 active exporters to 23 countries. The average shipment value is $1.0K.

Which countries import canagliflozin from India?

India exports canagliflozin to 23 countries. The top importing countries are SINGAPORE (60.0%), MAURITIUS (15.6%), BELGIUM (9.7%), SWITZERLAND (6.9%), TAIWAN (4.1%), which together account for 96.2% of total export value.

What is the HS code for canagliflozin exports from India?

The primary HS code for canagliflozin exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Canagliflozin

Canagliflozin

Top Canagliflozin Exporters from India

Top Countries Importing Canagliflozin from India

Who Supplies Canagliflozin to India?

Quick Facts

Related Advanced Diabetes Medications

Related Analysis

Need Details?

Regulatory Landscape — Canagliflozin

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Canagliflozin

Supply Chain Risk Assessment — Canagliflozin

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Canagliflozin Trade Intelligence

Frequently Asked Questions — Canagliflozin Exports from India

Who are the top canagliflozin exporters from India?

What is the total export value of canagliflozin from India?

Which countries import canagliflozin from India?

What is the HS code for canagliflozin exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of canagliflozin exports from India?

Which ports handle canagliflozin exports from India?

Why is India a leading exporter of canagliflozin?

What certifications do Indian canagliflozin exporters need?

How many buyers import canagliflozin from India?

What is the market share of the top canagliflozin exporter from India?

Analysis Methodology